Generic Central Nervous System Drugs Market Revenue Outlook: Strategic Insights and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Generic Central Nervous System Drugs Market Heading Into 2029?
The market size for generic drugs pertaining to the central nervous system has seen substantial growth in the past years. It is projected to ascend from $88.43 billion in 2024 to $93.53 billion in 2025, with a compound annual growth rate (CAGR) estimated at 5.8%. Factors such as the rise in the number of surgeries, robust expansion in emerging markets, boost in pharmaceutical research and development, older population, and surge in healthcare spending have contributed to growth during the historic period.
Over the forthcoming years, the general central nervous system drugs market is predicted to experience robust expansion, poised to increase to “$123.41 billion in 2029 with a 7.2% compound annual growth rate (CAGR).” This anticipated surge within the forecast period is due to factors such as enhanced government initiatives towards mental health awareness, escalated healthcare spending, a growing elderly population, and a dynamic drug pipeline. The forecast period trends encompass investment in wearable technology, the incorporation of biomarkers in CNS advancement, adjustment of existing drugs, focusing on drug pipeline investments, adopting 3D printing in drug production, and the emphasis on fostering partnerships with renowned research institutions and well-established companies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp
Which Factors Are Pushing The Generic Central Nervous System Drugs Market Forward?
The rise in mental health disorders is set to stimulate the expansion of the generic central nervous system (CNS) drug market in the future. These disorders cause significant impairment in a person’s cognitive abilities, emotional handling or behavioral patterns, often associated with distress or dysfunctional behavior in key aspects of life. Generic CNS drugs are pivotal in managing these disorders as they provide accessible and cost-effective treatment choices. For instance, the Health and Social Care Information Centre, a UK federal entity providing data, information, and computer systems for professionals, doctors, and administrators in the social and healthcare sectors, reported in November 2022 that the percentage of 17- to 19-year-olds presumed to have a mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the escalating prevalence of mental health disorders is fuelling the growth of the generic CNS drug market.
The generic central nervous system drugs market covered in this report is segmented –
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics
6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms
7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids
How Are Key Trends Driving Expansion In The Generic Central Nervous System Drugs Industry?
Key players in the generic central nervous system drugs market are prioritizing the creation of biosimilars for disorders related to the central nervous system (CNS). The emergence and approval of biosimilars for some biologic drugs utilized in CNS disorders are becoming increasingly prevalent, offering a less expensive alternative to patented biological drugs. For example, Sandoz, a pharmaceutical firm based in Switzerland, launched natalizumab-sztn in October 2023. This marks the inaugural biosimilar for the treatment of various forms of relapsing multiple sclerosis (MS), such as clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS, a chronic and progressive autoimmune illness, primarily influences the central nervous system. The bulk of individuals afflicted with the disease experience cycles of remission and relapse, causing a decrease in their quality of life. This treatment, however, will be prohibited for patients diagnosed with progressive multifocal leukoencephalopathy (PML) and those who have previously suffered from PML.
Which Organizations Are Driving Progress In The Generic Central Nervous System Drugs Industry?
Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram
Which Region Is Expected To Experience The Highest Growth In The Generic Central Nervous System Drugs Industry?
North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9315&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
